Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Summary of Financial Statements for the Fiscal Year Ended March 31, 2021 [IFRS] (Consolidated)

May 13, 2021

Company name: JMDC Inc.
Listing: Tokyo Stock Exchange
Stock code: 4483
URL: https://www.jmdc.co.jp/en/index
Representative: Yosuke Matsushima, President and CEO
Inquiries: Yuta Yamamoto, Vice President and CFO
TEL: +81-3-5733-5010

Scheduled date to hold an Ordinary General Meeting of Shareholders: June 25, 2021
Scheduled date to commence dividend payments: –
Scheduled date to file a Securities Report: June 28, 2021
Preparation of supplementary material on financial results: Yes
Holding of financial results presentation meeting: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended March 31, 2021 (from April 1, 2020 to March 31, 2021)

(1) Consolidated operating results

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2021	16,771	37.9	3,695	66.8	3,636	66.9	2,476	62.0
March 31, 2020	12,158	20.8	2,215	50.7	2,178	54.5	1,528	51.3

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
Fiscal year ended	Millions of yen	%	Millions of yen	%	Yen	Yen
March 31, 2021	2,476	62.0	2,474	61.7	46.54	43.48
March 31, 2010	1,528	51.3	1,530	51.6	31.46	29.99

	Equity attributable to owners of parent Profit ratio	Total assets Ratio of profit (loss) before tax	Revenue Operating profit ratio
Fiscal year ended	%	%	Yen
March 31, 2021	12.0	8.6	22.0
March 31, 2010	15.9	9.5	18.2

Reference: Equity method profit (loss) Fiscal year ended March 31, 2021 ¥- million-
Fiscal year ended March 31, 2020 ¥- million
EBITDA Fiscal year ended March 31, 2021 ¥4,867 million [50.0%]
Fiscal year ended March 31, 2020 ¥3,245 million [37.6%]

Notes: 1. The Company conducted a 2-for-1 share split of its ordinary shares on October 9, 2019, and a 2-for-1 share split of its ordinary shares on October 1, 2020. Basic earnings per share and diluted earnings per share have been calculated assuming that each share split was conducted at the beginning of the previous fiscal year.
2. EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent	Owners' equity per share
As of	Millions of yen	Millions of yen	Millions of yen	%	Yen
March 31, 2021	57,854	28,250	28,250	48.8	504.59
March 31, 2020	26,944	13,123	13,123	48.7	252.22

Note: The Company conducted a 2-for-1 share split of its ordinary shares on October 9, 2019, and a 2-for-1 share split of its ordinary shares on October 1, 2020. Owners' equity per share has been calculated assuming that the share split was conducted at the beginning of the previous fiscal year.

(3) Consolidated cash flows

	Cash flows from (used in) operating activities	Cash flows from (used in) investing activities	Cash flows from (used in) financing activities	Cash and cash equivalents balance at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
March 31, 2021	3,176	(9,078)	18,107	19,898
March 31, 2020	3,146	(3,947)	4,858	7,692

2. Cash dividends

	Annual dividends					Total dividend (Total)	Payout ratio (Consolidated)	Ratio of owners' equity to gross assets (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended March 31, 2020	–	0.00	–	0.00	0.00	–	–	–
Fiscal year ended March 31, 2021	–	0.00	–	0.00	0.00	–	–	–
Fiscal year ending March 31, 2022 (Forecast)	–	0.00	–	0.00	0.00		–	

3. Consolidated earnings forecasts for the fiscal year ending March 31, 2022 (from April 1, 2021 to March 31, 2022)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending September 30 (cumulative)	9,000	29.0	1,250	12.9	1,200	9.0	800	9.7	800	9.7	14.47
Fiscal year ending March 31, 2022	21,000	25.2	4,300	16.4	4,250	16.9	2,900	17.1	2,900	17.1	52.46

Reference: EBITDA Six months ending September 30, 2021 (cumulative) ¥2,100 million [26.2%]
Fiscal year ending March 31, 2022 ¥5,900 million [21.2%]

*** Notes**

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None

Added companies: - (company name), Excluded companies: - (company name)

(2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(3) Number of issued shares (ordinary shares)

(i) Total number of issued shares at end of the period (including treasury shares)

As of March 31, 2021	55,935,808 shares
As of March 31, 2020	51,950,084 shares

(ii) Number of treasury shares at end of the period

As of March 31, 2021	366 shares
As of March 31, 2020	46 shares

(iii) Average number of shares outstanding during the period

Fiscal year ended March 31, 2021	53,202,450 shares
Fiscal year ended March 31, 2020	48,583,682 shares

Note: The Company conducted a 2-for-1 share split of its ordinary shares on October 9, 2019, and a 2-for-1 share split of its ordinary shares on October 1, 2020. Total number of issued shares at end of the period, number of treasury shares at end of the period and average number of shares outstanding during the period have been calculated assuming that each share split was conducted at the beginning of the previous fiscal year.

(Reference) Outline of non-consolidated financial results

1. Non-consolidated financial results for the fiscal year ended March 31, 2021 (from April 1, 2020 to March 31, 2021)

(1) Non-consolidated operating results

	Revenue		Operating profit		Ordinary profit (loss)		Profit	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2021	6,318	32.9	1,098	24.9	1,035	24.7	734	37.5
March 31, 2020	4,755	32.1	879	13.7	830	10.2	534	38.0

	Basic earnings per share	Diluted earnings per share
Fiscal year ended	Yen	Yen
March 31, 2021	13.80	12.89
March 31, 2010	10.99	10.48

Note: The Company conducted a 2-for-1 share split of its ordinary shares on October 9, 2019, and a 2-for-1 share split of its ordinary shares on October 1, 2020. Basic earnings per share and diluted earnings per share have been calculated assuming that each share split was conducted at the beginning of the previous fiscal year.

(2) Non-consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
March 31, 2021	42,475	27,835	65.5	497.17
March 31, 2020	18,435	11,384	61.6	218.75

Reference: Equity Fiscal year ended March 31, 2021 ¥27,809 million
Fiscal year ended March 31, 2020 ¥11,364 million

Note: The Company conducted a 2-for-1 share split of its ordinary shares on October 9, 2019, and a 2-for-1 share split of its ordinary shares on October 1, 2020. Net assets per share has been calculated assuming that the share split was conducted at the beginning of the previous fiscal year.

*** Financial results reports are exempt from audits conducted by certified public accountants or an audit corporation.**

*** Proper use of earnings forecasts, and other special items**

Notes on forward-looking statements

The forward-looking statements, including earnings forecasts, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual business and other results may differ substantially due to various factors. For details regarding matters related to earnings forecasts, please refer to pages 4-5 of the attached materials.

How to obtain supplementary documents on financial results

Supplementary documents on financial results are released via TDnet on the same day.

Attached Material Index

1. Outline of business performance 2
(1) Outline of business performance for the fiscal year under review 2
(2) Outline of financial position for the fiscal year under review 4
(3) Outline of cash flows for the fiscal year under review 4
(4) Future outlook 4
2. Basic approach to the selection of accounting principles 5
3. Consolidated financial statements and significant notes thereto 6
(1) Consolidated statement of financial position 6
(2) Consolidated statement of profit or loss 7
(3) Consolidated statement of comprehensive income 8
(4) Consolidated statement of changes in equity 9
(5) Consolidated statement of cash flows 11
(6) Notes concerning the consolidated financial statements 12
Notes on going concern assumption 12
Segment information, etc. 12
Information per share 14
Significant subsequent events 14

1. Outline of business performance

(1) Outline of business performance for the fiscal year under review

JMDC Inc. (the "Company") is promoting the health of citizens, and delivering increased value of medical service providers and helping optimize their operations through gathering diverse data on the Japanese healthcare industry and thus benefiting society, with the aim of realizing a sustainable healthcare system by leveraging data and ICT.

In the Healthcare-Big Data segment, to promote the health services of health insurance associations, we provide analysis services for data held by health insurance associations as well as personal health record (PHR) services developed by the Company. We also provide services such as medical data analysis and medical factoring to medical institutions as well as medicine databases. Furthermore, we have created a database of anonymously processed information in the course of pursuing this business and are promoting scientific and industrial applications of this data.

In the Tele-medicine segment, we provide a matching service that connects medical institutions lacking a sufficient number of radiologists with contracted radiologists using a remote image interpretation system, as well as an ASP service that connects medical institutions with radiologists via the cloud to enable remote diagnostic imaging.

In the Dispensing Pharmacy Support segment, we develop and sell systems such as receipt computers and electronic medication history systems to health insurance pharmacies, and also conduct tests of our own systems as we operate our own dispensing pharmacies.

The Company's financial results for the fiscal year ended March 31, 2021, were as follows. Furthermore, the impact of COVID-19 during the fiscal year under review was limited.

(Operating results)

(Millions of yen)

Category	7th fiscal year (From April 1, 2019 to March 31, 2020)		8th fiscal year (From April 1, 2020 to March 31, 2021)		YoY change	
Revenue	12,158		16,771		4,613	37.9%
Operating profit	2,215		3,695		1,480	66.8%
EBITDA [Margin]	3,245	[26.7%]	4,867	[29.0%]	1,622	50.0%

(Segment results)

(Millions of yen)

Category		7th fiscal year (From April 1, 2019 to March 31, 2020)		8th fiscal year (From April 1, 2020 to March 31, 2021)		YoY change	
Healthcare-Big Data	Segment revenue	5,754		10,193		4,439	77.1%
	Segment profit [ratio]	2,120	[36.8%]	3,647	[35.8%]	1,527	72.0%
Tele-medicine	Segment revenue	3,885		4,046		161	4.1%
	Segment profit [ratio]	980	[25.2%]	1,224	[30.3%]	244	24.9%
Dispensing Pharmacy Support	Segment revenue	2,709		2,692		(17)	(0.6)%
	Segment profit [ratio]	335	[12.4%]	371	[13.8%]	36	10.7%
Adjustment	Segment revenue	(190)		(160)		30	-
	Segment profit	(191)		(376)		(185)	-
Total	Revenue	12,158		16,771		4,613	37.9%
	EBITDA [margin]	3,245	[26.7%]	4,867	[29.0%]	1,622	50.0%

Note: EBITDA is an objective indicator for judging the achievement of the JMDC Group's management policies and strategies or management objectives. The JMDC Group uses EBITDA to measure the performance of each segment and believes that it is a useful and necessary measure to more effectively assess the Group's performance. The formulas for calculating EBITDA and EBITDA margin are as follows.

- EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses
- EBITDA margin: EBITDA / Revenue x 100

Healthcare-Big Data

During the fiscal year ended March 31, 2021, there were various negative factors. Due to the spread of the novel coronavirus disease (COVID-19), face-to-face sales were curtailed and investment in medical

institutions was restrained as patients refrained from visiting hospitals. However, the business continues to expand.

The number of contracted health insurance associations, the number of IDs issued for the PepUp health information platform developed by the Company, and the annual transaction value per customer at pharmaceutical and insurance companies all increased on a year-over-year basis. Moreover, we are expanding PHR features by starting to provide, for example, the "PepUp medicine notebook" which automatically displays the medicine prescription history from the dispensing fee invoice (dispensing receipt) data.

At the same time, to prepare for future growth due to increases in the volume and variety of data, we continue to make proactive up-front investments focused on personnel.

As a result, segment revenue for the fiscal year ended March 31, 2021 was ¥10,193 million and segment profit (segment EBITDA) was ¥3,647 million.

Tele-medicine

During the fiscal year ended March 31, 2021, due to the spread of COVID-19, there was a decrease in the number of diagnostic imaging requests per medical institution due to the trends for patients other than those with COVID-19 to refrain from visiting hospitals or receiving medical examinations. However, signs of improvement were gradually seen after the lifting of the first declaration of a state of emergency, and revenue increased on a year-on-year basis as a result of the increase in the number of medical institutions utilizing remote image services.

We continue to take measures to expand our business, including the development of "AI-RAD," an artificial intelligence engine platform that assists in diagnostic imaging, and preparations for full-scale business development in China.

As a result, segment revenue for the fiscal year ended March 31, 2021 was ¥4,046 million and segment profit (segment EBITDA) was ¥1,224 million.

Dispensing Pharmacy Support

During the fiscal year ended March 31, 2021, we worked to cultivate new customers while securing replacement demand from existing customers. However, segment revenue remained on the same level on a year-on-year basis due to various factors. Given the spread of COVID-19, there was self-restraint in sales activities and restrained investment in dispensing pharmacies due to a decline in the number of visits to those pharmacies. In addition, there was a pullback in demand following the last minute surge in response to the consumption tax increase that occurred in the previous fiscal year.

Furthermore, sales of the next-generation "P-CUBEn" integrated electronic medication history receipt computer system started in March 2021.

As a result, segment revenue for the fiscal year ended March 31, 2021 was ¥2,692 million and segment profit (segment EBITDA) was ¥371 million.

As a result of the above, for the fiscal year ended March 31, 2021, revenue increased to ¥16,771 million, operating profit to ¥3,695 million, and EBITDA to ¥4,867 million. Adjustments to reconcile EBITDA to operating profit are as follows.

(Reconciliation of EBITDA to operating profit)

(Millions of yen)

	7th fiscal year (From April 1, 2019 to March 31, 2020)	8th fiscal year (From April 1, 2020 to March 31, 2021)
EBITDA	3,245	4,867
Depreciation and amortization	(889)	(1,168)
Other income	5	20
Other expenses	(145)	(23)
Operating profit	2,215	3,695

(2) Outline of financial position for the fiscal year under review

Assets

Assets at the end of the fiscal year under review were ¥57,854 million, an increase of ¥30,910 million compared with the end of the fiscal year ended March 31, 2020. This was primarily due to an increase of ¥12,206 million in cash and cash equivalents from the issuance of new shares through an international offering, an increase of ¥7,896 million in goodwill due to the increase of consolidated subsidiaries, and an increase of ¥5,760 million in trade and other receivables and an increase of ¥3,017 million in property, plant and equipment as a result of the expansion of business for medical providers.

Liabilities

Liabilities at the end of the fiscal year under review were ¥29,603 million, an increase of ¥15,782 million compared with the end of the fiscal year ended March 31, 2020.

This was primarily due to increases of ¥2,915 million in borrowings in current liabilities to acquire a consolidated subsidiary (NS PARTNERS CO., LTD.) and ¥5,456 million in borrowings in non-current liabilities including borrowings and an increase of ¥4,598 million in trade and other payables due to business expansion for medical providers.

Equity

Equity at the end of the fiscal year under review was ¥28,250 million, an increase of ¥15,127 million compared with the end of the fiscal year ended March 31, 2020. This was primarily due to an increase of ¥5,559 million in share capital and an increase of ¥7,090 million in capital surplus from the issuance of new shares through an international offering, and the recording of ¥2,476 million in profit.

(3) Outline of cash flows for the fiscal year under review

Cash and cash equivalents (“cash”) at the end of the fiscal year under review was ¥19,898 million, an increase of ¥12,206 million compared with the end of the fiscal year ended March 31, 2020.

Cash flows and factors affecting them for the fiscal year under review were as follows.

Cash flows from operating activities

Cash flows from operating activities amounted to ¥3,176 million, an increase of ¥30 million compared with the fiscal year ended March 31, 2020. This was primarily due to the recording of ¥3,636 million in profit before tax as well as depreciation and amortization of ¥1,168 million while recording income taxes paid of ¥1,245 million.

Cash flows from investing activities

Net cash used in investing activities amounted to ¥9,078 million, an increase of ¥5,131 million compared with the fiscal year ended March 31, 2020. This was primarily due to purchase of shares of subsidiaries resulting in change in scope of consolidation of ¥4,883 million, payments for loans receivable conducted for purchase of shares of subsidiaries of ¥2,874 million, and purchase of property, plant and equipment of ¥1,384 million.

Cash flows from financing activities

Cash flows from financing activities amounted to ¥18,107 million, an increase of ¥13,249 million compared with the fiscal year ended March 31, 2020. This was primarily due to the recording of ¥10,714 million in proceeds from issuance of shares from the issuance of new shares through an international offering and the recording of ¥2,622 million in proceeds from short-term borrowings and ¥6,394 million in proceeds from long-term borrowings.

(4) Future outlook

The Group will likely post increased revenue and profit for the fiscal year ending March 31, 2022.

(i) Healthcare-Big Data

The business performance will likely continue to expand as various players involved in healthcare prepare environments which are able to utilize and apply data for medical development. The segment will continue to actively make advance investments in order to achieve future growth by increasing data volumes and categories, etc.

(ii) Tele-medicine

The business performance will likely continue to expand by capturing the remote image needs at medical institutions.

(iii) Dispensing Pharmacy Support

The business performance will likely expand through the sales of new merchandise and the expansion of sales regions.

We presume that the novel coronavirus will affect the Group's business performance because the sales activities for the Healthcare-Big Data segment will slow down as people refrain from visiting health insurance unions and medical agencies, and demand for ad hoc sales by the segment (a service of extracting and analyzing the necessary data in response to individual requests) will be reined in temporarily. The Group's business performance will likely be affected in the Tele-medicine segment with non-novel coronavirus patients refraining from visiting hospitals and requests for diagnostic imaging services decreasing due to people's reluctance to do a medical checkup. In the Dispensing Pharmacy Support segment, the business performance of dispensing pharmacies that are directly operated by the Group is predicted to be affected as people will refrain from visiting medical agencies, which will in turn reduce the number of times they visit dispensing pharmacies. However, the business performance outlook is calculated on the basis that these developments will have an insignificant effect on the business performance.

As for the Group's consolidated financial results, we forecast ¥21,000 million in revenue (an increase of ¥4,229 million year on year), ¥4,300 million in operating profit (an increase of ¥605 million year on year), ¥4,250 million in profit before tax (an increase of ¥614 million year on year) and ¥2,900 million in profit attributable to owners of parent (an increase of ¥424 million year on year). EBITDA, which the Company deems to be an important business indicator, is forecast at ¥5,900 million (an increase of ¥1,033 million year on year).

The above-mentioned outlook is based on judgments and assumptions derived from information that is currently available to the Company, and the actual business performance in the future may differ significantly due to changes in the situation and impacts of the spread of the novel coronavirus.

2. Basic approach to the selection of accounting principles

Starting from the fiscal year ended March 31, 2019, the Group began to voluntarily adopt the International Financial Reporting Standards (IFRS) instead of Japanese GAAP in order to make its financial statements more comparable internationally in capital markets and unify the Group's accounting practices.

3. Consolidated financial statements and significant notes thereto

(1) Consolidated statement of financial position

(Millions of yen)

	As of March 31, 2020	As of March 31, 2021
Assets		
Current assets		
Cash and cash equivalents	7,692	19,898
Trade and other receivables	1,993	7,753
Other financial assets	0	152
Inventories	266	220
Other current assets	183	336
Total current assets	10,136	28,360
Non-current assets		
Property, plant and equipment	5,169	8,186
Goodwill	7,388	15,284
Intangible assets	1,971	3,718
Other financial assets	1,670	1,132
Deferred tax assets	568	975
Other non-current assets	41	196
Total non-current assets	16,808	29,493
Total assets	26,944	57,854
Liabilities and equity		
Liabilities		
Current liabilities		
Borrowings	373	3,288
Trade and other payables	1,244	5,842
Lease liabilities	392	621
Income taxes payable	657	768
Provisions	26	8
Other current liabilities	2,243	2,679
Total current liabilities	4,938	13,208
Non-current liabilities		
Borrowings	4,677	10,133
Lease liabilities	3,827	5,411
Retirement benefit liability	243	250
Provisions	131	190
Deferred tax liabilities	2	408
Total non-current liabilities	8,883	16,394
Total liabilities	13,821	29,603
Equity		
Share capital	3,412	8,971
Capital surplus	5,842	12,932
Treasury shares	(0)	(1)
Other components of equity	20	23
Retained earnings	3,847	6,323
Total equity attributable to owners of parent	13,123	28,250
Total equity	13,123	28,250
Total liabilities and equity	26,944	57,854

(2) Consolidated statement of profit or loss

(Millions of yen)

	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021
Revenue	12,158	16,771
Cost of sales	5,531	7,152
Gross profit	6,627	9,619
Selling, general and administrative expenses	4,271	5,920
Other income	5	20
Other expenses	145	23
Operating profit	2,215	3,695
Finance income	0	34
Finance costs	37	93
Profit before tax	2,178	3,636
Income tax expense	650	1,160
Profit	1,528	2,476
Profit attributable to		
Owners of parent	1,528	2,476
Profit	1,528	2,476
Earnings per share		
Basic earnings per share (Yen)	31.46	46.54
Diluted earnings per share (Yen)	29.99	43.48

(3) Consolidated statement of comprehensive income

(Millions of yen)

	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021
Profit	1,528	2,476
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	-	1
Remeasurements of defined benefit plans	2	(1)
Total of items that will not be reclassified to profit or loss	2	(0)
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	(0)	(1)
Total of items that may be reclassified to profit or loss	(0)	(1)
Other comprehensive income, net of tax	2	(2)
Comprehensive income	1,530	2,474
Comprehensive income attributable to		
Owners of parent	1,530	2,474
Comprehensive income	1,530	2,474

(4) Consolidated statement of changes in equity

Fiscal year ended March 31, 2020 (from April 1, 2019 to March 31, 2020)

(Millions of yen)

	Equity attributable to owners of parent				
				Other components of equity	
	Share capital	Capital surplus	Treasury shares	Exchange differences on translation of foreign operations	Remeasurements of defined benefit plans
Balance at beginning of period	646	3,142	–	–	–
Profit	–	–	–	–	–
Other comprehensive income	–	–	–	(0)	2
Total	–	–	–	(0)	2
Issuance of share acquisition rights	–	–	–	–	–
Share–based remuneration transactions	–	–	–	–	–
Exercise of share acquisition rights	22	22	–	–	–
Issuance of new shares	2,743	2,677	–	–	–
Purchase of treasury shares	–	–	(0)	–	–
Transfer to retained earnings	–	–	–	–	(2)
Total transactions with owners	2,766	2,700	(0)	–	(2)
Balance at end of period	3,412	5,842	(0)	(0)	–

	Equity attributable to owners of parent				
	Other components of equity				
	Share acquisition rights	Total	Retained earnings	Total	Total
Balance at beginning of period	11	11	2,317	6,117	6,117
Profit	–	–	1,528	1,528	1,528
Other comprehensive income	–	2	–	2	2
Total	–	2	1,528	1,530	1,530
Issuance of share acquisition rights	0	0	–	0	0
Share–based remuneration transactions	11	11	–	11	11
Exercise of share acquisition rights	(2)	(2)	–	43	43
Issuance of new shares	–	–	–	5,420	5,420
Purchase of treasury shares	–	–	–	(0)	(0)
Transfer to retained earnings	–	(2)	2	–	–
Total transactions with owners	9	6	2	5,475	5,475
Balance at end of period	20	20	3,847	13,123	13,123

Fiscal year ended March 31, 2021 (from April 1, 2020 to March 31, 2021)

(Millions of yen)

	Equity attributable to owners of parent					
				Other components of equity		
	Share capital	Capital surplus	Treasury shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans
Balance at beginning of period	3,412	5,842	(0)	(0)	–	–
Profit	–	–	–	–	–	–
Other comprehensive income	–	–	–	(1)	1	(1)
Total	–	–	–	(1)	1	(1)
Issuance of share acquisition rights	–	–	–	–	–	–
Share–based remuneration transactions	–	–	–	–	–	–
Exercise of share acquisition rights	202	211	–	–	–	–
Forfeiture of share acquisition rights	–	0	–	–	–	–
Issuance of new shares	5,357	5,324	–	–	–	–
Purchase of treasury shares	–	–	(1)	–	–	–
Increase due to business combination	–	5,147	–	–	–	–
Effect of business combinations under common control	–	(3,593)	–	–	–	–
Transfer to retained earnings	–	–	–	–	(1)	1
Total transactions with owners	5,559	7,090	(1)	–	(1)	1
Balance at end of period	8,971	12,932	(1)	(2)	–	–

	Equity attributable to owners of parent				Total
	Other components of equity				
	Share acquisition rights	Total	Retained earnings	Total	
Balance at beginning of period	20	20	3,847	13,123	13,123
Profit	–	–	2,476	2,476	2,476
Other comprehensive income	–	(2)	–	(2)	(2)
Total	–	(2)	2,476	2,474	2,474
Issuance of share acquisition rights	8	8	–	8	8
Share–based remuneration transactions	8	8	–	8	8
Exercise of share acquisition rights	(11)	(11)	–	401	401
Forfeiture of share acquisition rights	(0)	(0)	–	–	–
Issuance of new shares	–	–	–	10,682	10,682
Purchase of treasury shares	–	–	–	(1)	(1)
Increase due to business combination	–	–	–	5,147	5,147
Effect of business combinations under common control	–	–	–	(3,593)	(3,593)
Transfer to retained earnings	–	0	(0)	–	–
Total transactions with owners	5	5	(0)	12,653	12,653
Balance at end of period	25	23	6,323	28,250	28,250

(5) Consolidated statement of cash flows

(Millions of yen)

	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021
Net cash provided by (used in) operating activities		
Profit before tax	2,178	3,636
Depreciation and amortization	889	1,168
Decrease (increase) in trade and other receivables	(186)	9
Decrease (increase) in inventories	(99)	67
Increase (decrease) in trade and other payables	79	(459)
Other	565	18
Subtotal	3,427	4,441
Interest and dividends received	0	34
Interest paid	(35)	(53)
Income taxes paid	(245)	(1,245)
Net cash provided by (used in) operating activities	3,146	3,176
Cash flows from investing activities		
Purchase of property, plant and equipment	(343)	(1,384)
Purchase of intangible assets	(812)	(840)
Payments for loans receivable	–	(2,874)
Purchase of investments	(1,302)	(231)
Proceeds from sale and redemption of investments	–	951
Proceeds from purchase of shares of subsidiaries resulting in change in scope of consolidation	–	361
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(1,478)	(4,883)
Payments of leasehold and guarantee deposits	(7)	(194)
Other	(2)	16
Net cash provided by (used in) investing activities	(3,947)	(9,078)
Cash flows from financing activities		
Proceeds from short–term borrowings	–	2,622
Repayments of short–term borrowings	(1,790)	(840)
Proceeds from long–term borrowings	5,185	6,394
Repayments of long–term borrowings	(3,666)	(645)
Repayments of lease liabilities	(359)	(514)
Proceeds from issuance of shares	5,487	10,714
Proceeds from exercise of share acquisition rights	43	392
Other	(39)	(15)
Cash flows from financing activities	4,858	18,107
Net increase (decrease) in cash and cash equivalents	4,058	12,206
Cash and cash equivalents at beginning of period	3,634	7,692
Effect of exchange rate changes on cash and cash equivalents	(0)	0
Cash and cash equivalents at end of period	7,692	19,898

(6) Notes concerning the consolidated financial statements

Notes on going concern assumption

Not applicable.

Segment information, etc.

(1) Overview of reportable segments

The JMDC Group's reportable segments are components of the Group for which discrete financial information is available, and whose operating results are regularly reviewed by the Board of Directors to make decisions about managerial resources to be allocated to the segments and assess their performances. The JMDC Group consolidates multiple businesses based on the similarities in the nature of the services it provides and has three reportable segments: "Healthcare–Big Data," "Tele–medicine," and "Dispensing Pharmacy Support."

The main businesses and principal services included in each reportable segment are as follows.

Reportable segments	Main businesses	Main services
Healthcare–Big Data	Business for payers and individuals Business for healthcare providers Business for industry	Development and provision of medical databases (receipts, pharmaceuticals, etc.) and analysis of medical big data
Tele–medicine	Remote image interpretation matching service Remote image interpretation infrastructure	Provision of remote image interpretation matching service and remote image interpretation infrastructure systems
Dispensing Pharmacy Support	Dispensing pharmacy support business	Development and sales of business systems for dispensing pharmacies

(2) Computation method for the amount of revenue, profit or loss, and other items for each reporting segment

The accounting methods for the reportable segments are the same as those described in the accounting policies. Intersegment revenues are based on negotiated transaction prices, taking into account market prices and production costs.
The profits of reporting segments are in EBITDA.
EBITDA: Operating profit + Depreciation and amortization ± Other income and expenses

(3) Information on the amount of revenue, profit or loss, and other items for each reporting segment

Fiscal year ended March 31, 2020 (from April 1, 2019 to March 31, 2020)

(Millions of yen)

	Reportable segments				Adjustment (Note)	Consolidated
	Healthcare–Big Data	Tele–medicine	Dispensing Pharmacy Support	Total		
Revenue						
Revenue from external customers	5,723	3,885	2,549	12,158	–	12,158
Intersegment revenue	30	–	159	190	(190)	–
Total	5,754	3,885	2,709	12,348	(190)	12,158
Segment profit EBITDA	2,120	980	335	3,436	(191)	3,245
Other items Depreciation and amortization	598	215	75	889	–	889

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

Fiscal year ended March 31, 2021 (from April 1, 2020 to March 31, 2021)

(Millions of yen)

	Reportable segments				Adjustment (Note)	Consolidated
	Healthcare–Big Data	Tele–medicine	Dispensing Pharmacy Support	Total		
Revenue						
Revenue from external customers	10,160	4,046	2,564	16,771	–	16,771
Intersegment revenue	32	–	128	160	(160)	–
Total	10,193	4,046	2,692	16,932	(160)	16,771
Segment profit EBITDA	3,647	1,224	371	5,243	(376)	4,867
Other items Depreciation and amortization	825	257	84	1,168	0	1,168

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

A reconciliation of EBITDA to profit before tax is as follows.

(Millions of yen)

	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021
EBITDA	3,245	4,867
Depreciation and amortization	(889)	(1,168)
Other income	5	20
Other expenses	(145)	(23)
Operating profit	2,215	3,695
Finance income	0	34
Finance costs	(37)	(93)
Profit before tax	2,178	3,636

(4) Information about products and services

A listing of the products and service categories was omitted, because they are identical to the reportable segments.

(5) Information by region

Information by region was omitted because over 90% of the Group's total revenue was generated in Japan and its non–current assets are nearly entirely located in the country.

(6) Information about major customers

No revenue from transactions with a single external customer exceeds 10% of the Group's total revenue.

Information per share

(1) Basis for calculating the basic earnings per share

	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021
Profit attributable to owners of parent (Millions of yen)	1,528	2,476
Profit not attributable to ordinary shareholders of parent (Millions of yen)	–	–
Used to calculate the basic earnings per share Profit (Millions of yen)	1,528	2,476
Weighted average of the number of ordinary shares (thousands of shares)	48,584	53,202
Basic earnings per share (Yen)	31.46	46.54

(2) Basis for calculating the diluted earnings per share

	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021
Used to calculate the basic earnings per share		
Profit (Millions of yen)	1,528	2,476
Profit adjustment (Millions of yen)	–	–
Used to calculate the diluted earnings per share		
Profit (Millions of yen)	1,528	2,476
Weighted average of the number of ordinary shares (thousands of shares)	48,584	53,202
Increase in the number of ordinary shares		
Share acquisition rights (thousands of shares)	2,384	3,743
Weighted average of the number of ordinary shares after dilution (thousands of shares)	50,968	56,945
Diluted earnings per share (Yen)	29.99	43.48

(Note) The Company conducted a 2-for-1 share split of its ordinary shares on October 9, 2019, and a 2-for-1 share split of its ordinary shares on October 1, 2020. Basic earnings per share and diluted earnings per share have been calculated assuming that each share split was conducted at the beginning of the previous fiscal year.

Significant subsequent events

Not applicable.